AP NEWS
Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

September 11, 2019

BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab, its investigational BTK inhibitor zanubrutinib, and its investigational PARP inhibitor pamiparib, will be presented in seven oral presentations and four poster presentations at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China.

Oral Presentations:

Title: Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC) and Nasopharyngeal Carcinoma (NPC) Session: Lung Cancer Session 1 Date: Thursday, September 19 Time: 11:20 – 11:25 Location Auditorium, Level 1 Presenter Qing Zhou, M.D., Ph.D., Guangdong Provincial People’s Hospital

Tislelizumab for Relapsed/Refractory Classical Hodgkin Title: Lymphoma: Updated Follow-up Efficacy and Safety Results from a Phase 2 Study Session: Innovative Drug Clinical Data Session 1 Date: Thursday, September 19 Time: 14:30 – 14:40 Location Strait Hall, Level 2 Presenter: Yuqin Song, M.D., Ph.D., Beijing Cancer Hospital

Tislelizumab in Chinese Patients with Melanoma, Urothelial Title: Carcinoma (UC), and Renal Cell Carcinoma (RCC) Session: Kidney Cancer Session 4 Date: Thursday, September 19 Time: 16:35 – 16:40 Location Conference Room 2A, Level 2 Presenter: Lili Mao, M.D., Ph.D. Beijing Cancer Hospital

Tislelizumab in Chinese Patients with Esophageal Cancer (EC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC), Title: and Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Tumors Session: Advanced Gastric Cancer Session 3 Date: Friday, September 20 Time: 11:24 – 11:36 Location Banquet Hall 1, Level 2 Presenter: Lin Shen, M.D., Ph.D., Beijing Cancer Hospital

Safety and Efficacy in Patients with Long-Term Exposure Title: (LTE) to Tislelizumab, an Investigational Anti-PD-1 Antibody, in a First-in-Human Phase 1 Study Session: Immuno-Oncology Session 3 Date: Friday, September 20 Time: 11:54 – 12:00 Location Hall 1G, Level 1 Presenter Chia-Jui Yen, M.D., Ph.D., National Cheng Kung University Hospital

Title: Tislelizumab Plus Chemotherapy as First-Line Treatment for Chinese Patients with Lung Cancer Session: Lung Cancer Session 3 Date: Saturday, September 21 Time: 11:38 – 11:44 Location Auditorium, Level 1 Presenter: Zhijie Wang, M.D., Ph.D., Cancer Hospital, Chinese Academy of Medical Sciences

Tislelizumab in Combination with Chemotherapy as Title: Treatment for Chinese Patients with Esophageal Squamous Cell Carcinoma (ESCC) Session: Innovative Drug Clinical Data Session 1 Date: Saturday, September 21 Time: 14:30 – 14:40 Location Banquet Hall 2, Level 2 Presenter: Ru Jia, M.D., The Fifth Medical Center, General Hospital of the People’s Liberation Army

Poster Presentations:

Dose Escalation of Pamiparib in Chinese Patients with High- Title: Grade Non-Mucinous Ovarian Cancer (HGOC) or Advanced Triple-Negative Breast Cancer (TNBC) Board #: P-36 Date: Thursday, September 19 Time: Afternoon Location: Strait Hall Poster Area, Level 2 Presenter: Xiyan Mu, M.D., BeiGene

Zanubrutinib for Patients with Relapsed or Refractory Title: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Board #: P-45 Date: Friday, September 20 Time: Morning Location: Strait Hall Poster Area, Level 2 Presenter: Meng Ji, M.D., BeiGene

Zanubrutinib, a Highly Specific BTK Inhibitor in Chinese Title: Patients with Relapsed/Refractory B-cell Malignancies: Follow-up Report of a Phase 1 Trial in China Board #: P-46 Date: Friday, September 20 Time: Morning Location: Strait Hall Poster Area, Level 2 Presenter: Chenmu Du, M.D., BeiGene

The molecular binding mechanism of tislelizumab, an Title: investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab Board #: P-60 Date: Friday, September 20 Time: Morning Location: Strait Hall Poster Area, Level 2 Presenter: Ye Liu, Ph.D., BeiGene

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1

Investor Contact Media Contact Craig West Liza Heapes +1 857-302-5189 +1 857-302-5663 ir@beigene.com media@beigene.com

__________________________________1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.

All contents © copyright 2019 The Associated Press. All rights reserved.